Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2015

Open Access 01-01-2015 | Original paper

Objective allergy markers and risk of cancer mortality and hospitalization in a large population-based cohort

Authors: Niloofar Taghizadeh, Judith M. Vonk, Jeannette J. Hospers, Dirkje S. Postma, Elisabeth G. E. de Vries, Jan P. Schouten, H. Marike Boezen

Published in: Cancer Causes & Control | Issue 1/2015

Login to get access

Abstract

Purpose

There are indications that a history of allergy may offer some protection against cancer. We studied the relation of three objectively determined allergy markers with cancer mortality and hospitalization risk.

Methods

Associations between three allergy markers (number of peripheral blood eosinophil counts, skin test positivity, and serum total IgE) with mortality and hospitalization from any type and four common types of cancer (lung, colorectal, prostate, and breast cancer) were assessed in the Vlagtwedde–Vlaardingen cohort (1965–1990), with follow-up of mortality until 31 December 2008. Hospitalization data were available since 1 January 1995.

Results

There were no significant associations between objective allergy markers and cancer mortality or hospitalization. We found several associations in specific subgroups. A higher number of eosinophils was associated with a decreased risk of colorectal cancer mortality in ever smokers HR (95 % CI) = 0.61 (0.45–0.83) and in males 0.59 (0.42–0.83); however, no overall association was observed 0.84 (0.64–1.09). Skin test positivity was associated with a decreased risk of any cancer mortality only among females 0.59 (0.38–0.91) and showed no overall association 0.83 (0.67–1.04). Serum total IgE levels were associated with an increased risk of lung cancer mortality among females 4.64 (1.04–20.70), but with a decreased risk of cancer hospitalization in ever smokers 0.77 (0.61–0.97) and males 0.72 (0.55–0.93); however, no overall associations were observed [mortality 0.99 (0.79–1.25), and hospitalization 0.86 (0.71–1.04)].

Conclusions

We found no associations between objective allergy markers and cancer in the total population. However, skin test positivity and a high number of eosinophils were associated with a reduced risk to die of cancer in specific subgroups. Hence, it seems important to study specific subgroups defined by gender and smoking habits in order to identify allergy markers of predictive value for cancer mortality.
Appendix
Available only for authorised users
Literature
1.
Wang H, Diepgen TL (2005) Is atopy a protective or a risk factor for cancer? A review of epidemiological studies. Allergy 60:1098–1111PubMedCrossRef
2.
3.
Turner MC, Chen Y, Krewski D, Ghadirian P (2006) An overview of the association between allergy and cancer. Int J Cancer 118:3124–3132PubMedCrossRef
4.
Merrill RM, Isakson RT, Beck RE (2007) The association between allergies and cancer: what is currently known? Ann Allergy Asthma Immunol 99:102–116PubMedCrossRef
5.
6.
Wang H, Rothenbacher D, Low M, Stegmaier C, Brenner H, Diepgen TL (2006) Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum. Int J Cancer 119:695–701PubMedCrossRef
7.
Sherman PW, Holland E, Sherman JS (2008) Allergies: their role in cancer prevention. Q Rev Biol 83:339–362PubMedCrossRef
8.
Josephs DH, Spicer JF, Corrigan CJ, Gould HJ, Karagiannis SN (2013) Epidemiological associations of allergy, IgE and cancer. Clin Exp Allergy 43:1110–1123PubMed
9.
Olson SH, Hsu M, Satagopan JM, Maisonneuve P, Silverman DT, Lucenteforte E et al (2013) Allergies and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control Consortium. Am J Epidemiol 178:691–700PubMedCentralPubMedCrossRef
10.
Hsiao JR, Ou CY, Lo HI, Huang CC, Lee WT, Huang JS et al (2013) Allergies and risk of head and neck cancer: an original study plus meta-analysis. PLoS One 8:e55138PubMedCentralPubMedCrossRef
11.
Talbot-Smith A, Fritschi L, Divitini ML, Mallon DF, Knuiman MW (2003) Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort. Am J Epidemiol 157:606–612PubMedCrossRef
12.
Hospers JJ, Schouten JP, Weiss ST, Postma DS, Rijcken B (2000) Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample. Epidemiology 11:261–268PubMedCrossRef
13.
van der Lende R, Kok TJ, Reig RP, Quanjer PH, Schouten JP, Orie NG (1981) Decreases in VC and FEV1 with time: indicators for effects of smoking and air pollution. Bull Eur Physiopathol Respir 17:775–792PubMed
14.
Mensinga TT, Schouten JP, Rijcken B, Weiss ST, Speizer FE, Van der Lende R (1990) The relationship of eosinophilia and positive skin test reactivity to respiratory symptom prevalence in a community-based population study. J Allergy Clin Immunol 86:99–107PubMedCrossRef
15.
Jansen DF, Rijcken B, Schouten JP, Kraan J, Weiss ST, Timens W, Postma DS (1999) The relationship of skin test positivity, high serum total IgE levels, and peripheral blood eosinophilia to symptomatic and asymptomatic airway hyperresponsiveness. J AM Respir Med 159:924–931CrossRef
16.
Prentice RL, Kalbfleisch JD, Peterson AV, Flournoy N Jr, Farewell VT, Breslow NE (1978) The analysis of failure times in the presence of competing risks. Biom J 34:541–554
17.
Rittmeyer D, Lorentz A (2012) Relationship between allergy and cancer: an overview. Int Arch Allergy Immunol 159:216–225PubMedCrossRef
18.
Turner MC (2012) Epidemiology: allergy history, IgE, and cancer. Cancer Immunol Immunother 61:1493–1510PubMedCrossRef
19.
Vojtechova P, Martin RM (2009) The association of atopic diseases with breast, prostate, and colorectal cancers: a meta-analysis. Cancer Causes Control 20:1091–1105PubMedCrossRef
20.
Eriksson NE, Mikoczy Z, Hagmar L (2005) Cancer incidence in 13811 patients skin tested for allergy. J Investig Allergol Clin Immunol 15:161–166PubMed
21.
Lowcock EC, Cotterchio M, Ahmad N (2013) Association between allergies, asthma, and breast cancer risk among women in Ontario, Canada. Cancer Causes Control 24:1053–1056PubMedCrossRef
22.
Mensinga TT (1993) Smoking modifies the relationship of markers of allergy to eosinophil count in a community-based population study. In: Thesis, University of Groningen, Groningen, The Netherlands vol 3, pp 39–58
23.
Tanaka T, Ozaki K (2006) Inflammation as a risk factor for myocardial infarction. J Hum Genet 51:595–604PubMedCrossRef
24.
Legrand F, Driss V, Delbeke M, Loiseau S, Hermann E, Dombrowicz D et al (2010) Human eosinophils exert TNF-α and granzyme A-mediated tumoricidal activity toward colon carcinoma cells. J Immunol 185:7443–7451PubMedCrossRef
25.
Munitz A, Levi-Schaffer F (2004) Eosinophils: ‘new’ roles for ‘old’ cells. Allergy 59:268–275PubMedCrossRef
26.
Chen W, Mempel M, Schober W, Behrendt H, Ring J (2008) Gender difference, sex hormones, and immediate type hypersensitivity reactions. Allergy 63:1418–1427PubMedCrossRef
27.
Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M et al (2008) AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy 63:1255–1266PubMedCentralPubMedCrossRef
28.
Turner MC, Chen Y, Krewski D, Ghadirian P, Thun MJ, Calle EE (2005) Cancer mortality among US men and women with asthma and hay fever. Am J Epidemiol 162:212–221PubMedCrossRef
Metadata
Title
Objective allergy markers and risk of cancer mortality and hospitalization in a large population-based cohort
Authors
Niloofar Taghizadeh
Judith M. Vonk
Jeannette J. Hospers
Dirkje S. Postma
Elisabeth G. E. de Vries
Jan P. Schouten
H. Marike Boezen
Publication date
01-01-2015
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 1/2015
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-014-0489-9

Other articles of this Issue 1/2015

Cancer Causes & Control 1/2015 Go to the issue

Original paper

Circadian clock genes and risk of fatal prostate cancer

Original paper

Hardcore smoking among continuing smokers in Canada 2004–2012

Original paper

Obesity and head and neck cancer risk and survival by human papillomavirus serology

Brief report

International testicular cancer incidence trends: generational transitions in 38 countries 1900–1990

Original paper

Shift work and breast cancer among women textile workers in Shanghai, China

Original paper

A randomized controlled trial of two interventions to increase colorectal cancer screening among Hispanics on the Texas–Mexico border
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits